{"id":"NCT00494507","sponsor":"University of Rochester","briefTitle":"Hyper- and Hypokalemic Periodic Paralysis Study","officialTitle":"Dichlorphenamide vs. Placebo for Periodic Paralysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2013-04","completion":"2013-05","firstPosted":"2007-06-29","resultsPosted":"2014-05-30","lastUpdate":"2017-06-14"},"enrollment":71,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperkalemic Periodic Paralysis","Hypokalemic Periodic Paralysis"],"interventions":[{"type":"DRUG","name":"Dichlorphenamide (double-blind)","otherNames":["Daranide"]},{"type":"DRUG","name":"Placebo (double-blind)","otherNames":[]},{"type":"DRUG","name":"Dichlorphenamide (open-label)","otherNames":["Daranide"]}],"arms":[{"label":"HYP Dichlorphenamide","type":"ACTIVE_COMPARATOR"},{"label":"HYP Placebo","type":"PLACEBO_COMPARATOR"},{"label":"HOP Dichlorphenamide","type":"ACTIVE_COMPARATOR"},{"label":"HOP Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.","primaryOutcome":{"measure":"HYP Attack Rate","timeFrame":"8 weeks","effectByArm":[{"arm":"HYP Dichlorphenamide","deltaMin":0.9,"sd":null},{"arm":"HYP Placebo","deltaMin":4.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":12,"countries":["United States","Italy","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":12},"commonTop":["PARAESTHESIA","COGNITIVE DISORDER","DYSGEUSIA","FALL","HEADACHE"]}}